Presenters
Associate Professor
Professor Alice Cheng
Associate Editor of Diabetologia
Professor Per-Henrik Groop
German Society of Cardiology
Professor Michael Bohm
Director of the Diabetes Centre and Diabetes Services
Professor Ted Wu
Professor of Physiology
Professor Javed Butler
Course Details
This course focuses on Empagliflozin (Jardiance) and Empagliflozin + Linagliptin (Glyxambi). In patients with T2D, empagliflozin have been shown to improve metabolic risk factors, reduce the risk of CV and kidney complications, and have an established safety profile. Empagliflozin + Linagliptin (Glyxambi®) contains the individual components empagliflozin and linagliptin with
metabolic benefits of powerful HbA1c reduction and safety profile similar to the individual components.
Estimated time of Completion: 11 Minutes
CPD Point: 1 Point
Program No: PROG-2024-89343
Module 5 - Brands
| Time | Topic | Speaker |
|---|---|---|
| 1:29 Minutes | Communication of CV Death Risk Reduction Benefits of Empagliflozin | Prof Michael Bohm |
| 1:34 Minutes | Effective Communication on benefits of Empagliflozin | Prof Alice Cheng |
| 1:27 Minutes | Empagliflozin: The Choice of Foundational Treatment for Long Term Beneficial Outcomes | Prof Ted Wu |
| 2:53 Minutes | Empagliflozin CV Protection's Value for T2D Patients | Prof Javed Butler |
| 3:41 Minutes | Practical Tips in SGLT2i initiation | |
| 1:51 Minutes | Empagliflozin + Linagliplin Renal Protection and Safety in T2D Management | Prof Per-Henrik Groop |
| 1:20 Minutes | Empagliflozin + Linagliptin Benefit to T2D Patients with No Established CV Disease | Prof Michael Bohm |
| 4:19 Minutes | Empagliflozin + Linagliptin Cardio Renal Metabolic Protection |
Production Date: July 2024
PC-PH-105916